Citations

Clear

912 citation(s) found for "Yu, Caroline".

A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma
Brown, Paul D. , Chung, Caroline , Liu, Diane D. , McAvoy, Sarah , Grosshans, David R. , Mahajan, Anita , McGovern, Susan L. , McAleer, Mary-Fran, Ghia, Amol J. , Sulman, Erik P. , Peñas-Prado, Marta , Heimberger, Amy B. , Guha‐Thakurta, Nandita , Sulman, Erik P , Feghali, Karine A. Al , Li, Jing , McAleer, Mary Frances , Groot, John de , Heimberger, Amy B. , Wang, Jihong , Armstrong, Terri S. , Gilbert, Mark R. , Wefel, Jeffrey S.

Mayo Clinic

Neuro-Oncology | February 10, 2021 | Volume: 23 | Issue: 8 | Pages: 1337-1347

10.1093/neuonc/noab040 | PMID 33647972 Get It

Abstract Background To determine if proton radiotherapy (PT), compared to intensity-modulated radiotherapy (IMRT), delayed time to cognitive failure in patients with newly diagnosed glioblastoma (GBM). Methods Eligible patients were randomized unblinded to PT vs IMRT. The primary endpoint was time to cognitive failure. Secondary endpoints included overall survival (OS), intracranial progression-free survival (PFS), toxicity, and patient-reported outcomes (PROs). Results A total of 90 patients were enrolled and 67 were evaluable with median follow-up of 48.7 months (range 7.1-66.7). There was no significant difference in time to cognitive failure between treatment arms (HR, 0.88; 95% CI, 0.45-1.75; P = .74). PT was associated with a lower rate of fatigue (24% vs 58%, P = .05), but otherwise, there were no significant differences in PROs at 6 months. There was no difference in PFS (HR, 0.74; 95% CI, 0.44-1.23; P = .24) or OS (HR, 0.86; 95% CI, 0.49-1.50; P = .60). However, PT significantly reduced the radiation dose for nearly all structures analyzed. The average number of grade 2 or higher toxicities was significantly higher in patients who received IMRT (mean 1.15, range 0-6) compared to PT (mean 0.35, range 0-3; P = .02). Conclusions In this signal-seeking phase II trial, PT was not associated with a delay in time to cognitive failure but did reduce toxicity and patient-reported fatigue. Larger randomized trials are needed to determine the potential of PT such as dose escalation for GBM and cognitive preservation in patients with lower-grade gliomas with a longer survival time.
Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis
Goyal, Gaurav , Abeykoon, Jithma P. , Hu, Marie , Call, Timothy G. , Hook, C. Christopher , Pardanani, Animesh , Inwards, David J. , Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Ravindran, Aishwarya , Pardanani, Animesh , Inwards, David J , Ryu, Jay H , Ravindran, Aishwarya , Goyal, Guarav , Vassallo, Robert , Hu, Marie , Young, Jason R. , Shah, Meera , Bennani, N. Nora , Tobin, W. Oliver , Koster, Matthew J. , Rech, Karen L. , Go, Ronald S.

Mayo Clinic

American Journal of Hematology | February 7, 2021 | Volume: 96 | Issue: 5 | Pages: No page available

10.1002/ajh.26119 | PMID 33539584 Get It

WoCoVA consensus on the clinical use of in-line filtration during intravenous infusions: Current evidence and recommendations for future research
Boxtel, Ton van , Pittiruti, Mauro , Arkema, A., Ball, Patrick , Bertoglio, Sergio , Biffi, Roberto , Dupont, Christian , Fonzo‐Christe, Caroline, Foster, Jann , Keck, Cornelia M. , Ray‐Barruel, Gillian , Sasse, Michael , Hadaway, Lynn, Ryder, Marcia, Schears, Gregory, Stone, Josie, Van Boxtel, Ton , Bertoglio, Sergio , Biffi, Roberto , Barone, Giovanni , Jones, Matthew, Scoppettuolo, Giancarlo , Hoogen, Agnes van den , Villa, Gianluca

Mayo Clinic

The Journal of Vascular Access | January 28, 2021 | Volume: 23 | Issue: 2 | Pages: 179-191

10.1177/1129729821989165 | PMID 33506747 Get It

The need for filtering intravenous infusions has long been recognized in the field of venous access, though hard scientific evidence about the actual indications for in-line filters has been scarce. In the last few years, several papers and a few clinical studies have raised again this issue, suggesting that the time has come for a proper definition of the type of filtration, of its potential benefit, and of its proper indications in clinical practice. The WoCoVA Foundation, whose goal is to increase the global awareness on the risk of intravenous access and on patients’ safety, developed the project of a consensus on intravenous filtration. A panel of experts in different aspects of intravenous infusion was chosen to express the current state of knowledge about filtration and to indicate the direction of future research in this field. The present document reports the final conclusions of the panel.
A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer
Nounu, Aayah , Greenhough, Alexander , Heesom, Kate J. , Richmond, Rebecca C. , Weinstein, Stephanie J. , Baron, John A. , Figueiredo, Jane C. , Lindor, Noralane M. , Casey, Graham , Duijnhoven, Fränzel J.B. van , Gsur, Andrea , Vodička, Pavel , Vodičková, Ludmila, Brenner, Hermann , Chang‐Claude, Jenny , Hoffmeister, Michael , Slattery, Martha L. , Gunter, Marc J. , Kim, Hyeong Rok , Li, Li , Bishop, D. Timothy , Gruber, Stephen B. , Rennert, Gad , Harrison, Tabitha A. , Woods, Michael O. , Schafmayer, Clemens , Guelpen, Bethany Van , Gallinger, Steven , Berndt, Sonja I. , Lindblom, Annika , Wu, Anna H. , White, Emily , Peters, Ulrike , Drew, David A. , Scherer, Dominique , Relton, Caroline L. , Weinstein, Stephanie J , Baron, John A , Platz, Elizabeth A. , van Duijnhoven, Fränzel J B , Gsur, Andrea , Moreno, Victor , Brenner, Hermann , Chang-Claude, Jenny , Hoffmeister, Michael , Sakoda, Lori C , Slattery, Martha L , Schoen, Robert E , Castellví-Bel, Sergi , Kweon, Sun-Seog , Bishop, D Timothy , Buchanan, Daniel D , Giles, Graham G , Gruber, Stephen B , Harrison, Tabitha A , Woods, Michael O , Van Guelpen, Bethany , Hampel, Heather , Pharoah, Paul D P , Wolk, Alicja , Drew, David A , Scherer, Dominique , Rennert, Gad , Gunter, Marc J , Vodicka, Pavel , Lindblom, Annika , Zheng, Jie , Albanes, Demetrius , Hopper, John L. , Newcomb, Polly A. , Marchand, Loı̈c Le , Ulrich, Cornelia M. , Li, Christopher I , Campbell, Peter T. , Moreno, Vı́ctor , Sakoda, Lori C. , Schoen, Robert E. , Castellvı́-Bel, Sergi , Chan, Andrew T. , Zheng, Wei , Buchanan, Daniel D. , Giles, Graham G. , Stadler, Zsofia , Lin, Yi , Keku, Temitope O , Hampel, Heather , Pharoah, Paul D.P. , Wolk, Alicja , Bermejo, Justo Lorenzo , Williams, Ann Caroline

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 28, 2021 | Volume: 30 | Issue: 3 | Pages: 564-575

10.1158/1055-9965.epi-20-1176 | PMID 33318029 Get It

Abstract Background: Evidence for aspirin's chemopreventative properties on colorectal cancer (CRC) is substantial, but its mechanism of action is not well-understood. We combined a proteomic approach with Mendelian randomization (MR) to identify possible new aspirin targets that decrease CRC risk. Methods: Human colorectal adenoma cells (RG/C2) were treated with aspirin (24 hours) and a stable isotope labeling with amino acids in cell culture (SILAC) based proteomics approach identified altered protein expression. Protein quantitative trait loci (pQTLs) from INTERVAL (N = 3,301) and expression QTLs (eQTLs) from the eQTLGen Consortium (N = 31,684) were used as genetic proxies for protein and mRNA expression levels. Two-sample MR of mRNA/protein expression on CRC risk was performed using eQTL/pQTL data combined with CRC genetic summary data from the Colon Cancer Family Registry (CCFR), Colorectal Transdisciplinary (CORECT), Genetics and Epidemiology of Colorectal Cancer (GECCO) consortia and UK Biobank (55,168 cases and 65,160 controls). Results: Altered expression was detected for 125/5886 proteins. Of these, aspirin decreased MCM6, RRM2, and ARFIP2 expression, and MR analysis showed that a standard deviation increase in mRNA/protein expression was associated with increased CRC risk (OR: 1.08, 95% CI, 1.03–1.13; OR: 3.33, 95% CI, 2.46–4.50; and OR: 1.15, 95% CI, 1.02–1.29, respectively). Conclusions: MCM6 and RRM2 are involved in DNA repair whereby reduced expression may lead to increased DNA aberrations and ultimately cancer cell death, whereas ARFIP2 is involved in actin cytoskeletal regulation, indicating a possible role in aspirin's reduction of metastasis. Impact: Our approach has shown how laboratory experiments and population-based approaches can combine to identify aspirin-targeted proteins possibly affecting CRC risk.
Tristetraprolin expression by keratinocytes protects against skin carcinogenesis
Assabban, Assiya , Dubois-Vedrenne, Ingrid, Maele, Laurye Van , Salcedo, Rosalba, Snyder, Brittany L. , Zhou, Lecong , Azouz, Abdulkader , Toeuf, Bérengère de de , Lapouge, Gaëlle, La, Caroline, Melchior, Maxime, Nguyen, Muriel, Thomas, Séverine , Wu, Si , Hu, Wenqian , Kruys, Véronique , Blanpain, Cédric , Hu, Wenqian , Thomas, Séverine, Trinchieri, Giorgio , Gueydan, Cyril , Blackshear, Perry J. , Goriely, Stanislas

Mayo Clinic

JCI Insight | January 26, 2021 | Volume: 6 | Issue: 5 | Pages: No page available

10.1172/jci.insight.140669 | PMID 33497366 Get It

Cancer is caused primarily by genomic alterations resulting in deregulation of gene regulatory circuits in key growth, apoptosis, or DNA repair pathways. Multiple genes associated with the initiation and development of tumors are also regulated at the level of mRNA decay, through the recruitment of RNA-binding proteins to AU-rich elements (AREs) located in their 3′-untranslated regions. One of these ARE-binding proteins, tristetraprolin (TTP; encoded by Zfp36 ), is consistently dysregulated in many human malignancies. Herein, using regulated overexpression or conditional ablation in the context of cutaneous chemical carcinogenesis, we show that TTP represents a critical regulator of skin tumorigenesis. We provide evidence that TTP controlled both tumor-associated inflammation and key oncogenic pathways in neoplastic epidermal cells. We identify Areg as a direct target of TTP in keratinocytes and show that EGFR signaling potentially contributed to exacerbated tumor formation. Finally, single-cell RNA-Seq analysis indicated that ZFP36 was downregulated in human malignant keratinocytes. We conclude that TTP expression by epidermal cells played a major role in the control of skin tumorigenesis.
Moderate Exercise Inhibits Age-Related Inflammation, Liver Steatosis, Senescence, and Tumorigenesis
Bianchi, Arianna, Marchetti, Letizia , Lemos, Henrique , Vacca, Michèle , Paish, Hannah L. , Green, Kile , Elliott, Bronte, Passos, João F. , Jurk, Diana , Mann, Derek A. , Wilson, Caroline, Lemos, Henrique , Vacca, Michele , Jurk, Diana , Wilson, Caroline L , Passos, João F , Hall, Zoe , Tiniakos, Dina

Mayo Clinic

The Journal of Immunology | January 13, 2021 | Volume: 206 | Issue: 4 | Pages: 904-916

10.4049/jimmunol.2001022 | PMID 33441438 Get It

Abstract Age-related chronic inflammation promotes cellular senescence, chronic disease, cancer, and reduced lifespan. In this study, we wanted to explore the effects of a moderate exercise regimen on inflammatory liver disease and tumorigenesis. We used an established model of spontaneous inflammaging, steatosis, and cancer (nfkb1−/− mouse) to demonstrate whether 3 mo of moderate aerobic exercise was sufficient to suppress liver disease and cancer development. Interventional exercise when applied at a relatively late disease stage was effective at reducing tissue inflammation (liver, lung, and stomach), oxidative damage, and cellular senescence, and it reversed hepatic steatosis and prevented tumor development. Underlying these benefits were transcriptional changes in enzymes driving the conversion of tryptophan to NAD+, this leading to increased hepatic NAD+ and elevated activity of the NAD+-dependent deacetylase sirtuin. Increased SIRT activity was correlated with enhanced deacetylation of key transcriptional regulators of inflammation and metabolism, NF-κB (p65), and PGC-1α. We propose that moderate exercise can effectively reprogram pre-established inflammatory and metabolic pathologies in aging with the benefit of prevention of disease.
Primary mesenteric sarcomas: Collaborative experience from the Trans‐Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)
Tattersall, Hannah L. , Hodson, James , Cardona, Kenneth , Lee, Rachel , Gladdy, Rebecca A. , Hage, Jos A. van der , Schrage, Yvonne , Tseng, William W. , Novak, Marko , Grignani, Giovanni , Tolomeo, Francesco , Ryon, Emily L. , Arnau, Ana Belén Martín , Sayyed, Raza , Tirotta, Fabio , Evenden, Caroline, Glasbey, James , Ford, Samuel , Lee, Rachel M , Tseng, William W , Bagaria, Sanjay P , Tirotta, Fabio , Fiore, Marco , Grignani, Giovanni , Nessim, Carolyn , Houdt, Winan J. van , Goel, Neha , Gyorki, David E. , Bagaria, Sanjay P. , Gonzalez, Jose A., Desai, Anant , Almond, Max , Fiore, Marco , Gronchi, Alessandro

Mayo Clinic

Journal of Surgical Oncology | December 24, 2020 | Volume: 123 | Issue: 4 | Pages: 1057-1066

10.1002/jso.26353 | PMID 33368277 Get It

AbstractBackgroundPrimary mesenteric soft tissue sarcomas (STS) are rare and limited evidence is available to inform management. Surgical resection is challenging due to the proximity of vital structures and a need to preserve enteric function.ObjectivesTo determine the overall survival (OS) and recurrence‐free survival (RFS) for patients undergoing primary resection for mesenteric STS.MethodsThe Trans‐Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) is an intercontinental collaborative comprising specialist sarcoma centers. Data were collected retrospectively for all patients with mesenteric STS undergoing primary resection between 2000 and 2019.ResultsFifty‐six cases from 15 institutions were included. The spectrum of pathology was similar to the retroperitoneum, although of a higher grade. R0/R1 resection was achieved in 87%. Median OS was 56 months. OS was significantly shorter in higher‐grade tumors (p = .018) and extensive resection (p < .001). No significant association between OS and resection margin or tumor size was detected. Rates of local recurrence (LR) and distant metastases (DM) at 5 years were 60% and 41%, respectively. Liver metastases were common (60%), reflecting portal drainage of the mesentery.ConclusionPrimary mesenteric sarcoma is rare, with a modest survival rate. LR and DM are frequent events. Liver metastases are common, highlighting the need for surveillance imaging.
Proper Care of Transgender and Gender Diverse Persons in the Setting of Proposed Discrimination: A Policy Perspective*
Walch, Abby , Davidge‐Pitts, Caroline , Tangpricha, Vin , Tangpricha, Vin , Safer, Joshua D. , López, Ximena , Iwamoto, Sean J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 16, 2020 | Volume: 106 | Issue: 2 | Pages: 305-308

10.1210/clinem/dgaa816 | PMID 33326028 Get It

Abstract Transgender and gender diverse (TGD) individuals face significant barriers to accessing health care. Recent introductions of regulatory policies at state and federal levels raise concerns over the politicization of gender-affirming health care, the risks of further restricting access to quality care, and the potential criminalization of healthcare professionals who care for TGD patients. The Endocrine Society and the Pediatric Endocrine Society have published several news articles and comments in the last couple of years supporting safe and effective gender-affirming interventions as outlined in the 2017 Endocrine Society’s Clinical Practice Guidelines. The Endocrine Society Position Statement on Transgender Health also acknowledges the rapid expansion in understanding the biological underpinning of gender identity and the need for increased funding to help close gaps in knowledge about the optimal care of TGD individuals. This Policy Perspective affirms these principles in the context of pending and future legislation attempting to discriminate against TGD patients while also stressing the need for science and health care experts to inform health policies.
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
Dillmon, Melissa S., Levit, Laura A. , Moushey, E. Allyn, Alva, Ajjai , Blau, Sibel , Dickson, Natalie R. , Gönen, Mithat , González, Maria Magdalena, Hensold, Jack O. , Hinyard, Leslie , King, Tari A. , Lindsey, Stacie , Magnuson, Allison , Marron, Jonathan M. , Mcaneny, Barbara , McDonnell, Theresa Margaret, Nasso, S, Nowakowski, Grzegorz S. , Oettel, Kurt R., Patel, Manali I. , Patt, Debra A. , Perlmutter, Jane , Pickard, Todd , Rodriguez, Gladys , Rosenberg, Abby R. , Russo, Barry, Szczepanek, Connie M. , Smith, Cardinale B. , Teplinsky, Eleonora , Thota, Ramya , Zoň, Robin , Bourbeau, Brian , Foster, Shelagh E., Grubbs, Stephen, Hagerty, Karen L., Hurley, Patricia A. , Kamin, Deborah Y., Phillips, Jonathan , Schilsky, Richard L. , Burris, Howard A. , Hurley, Patricia , Rosenberg, Abby R , Pennell, Nathan A , Cannon, Timothy Lewis , Diehn, Maximilian , Mileham, Kathryn Finch , Srivastava, Piyush, Traina, Tiffany A , Bruinooge, Suanna S. , Schenkel, Caroline

Mayo Clinic

Journal of Clinical Oncology | December 8, 2020 | Volume: 39 | Issue: 2 | Pages: 155-169

10.1200/jco.20.02953 | PMID 33290128 Get It

This report presents the American Society of Clinical Oncology’s (ASCO’s) evaluation of the adaptations in care delivery, research operations, and regulatory oversight made in response to the coronavirus pandemic and presents recommendations for moving forward as the pandemic recedes. ASCO organized its recommendations for clinical research around five goals to ensure lessons learned from the COVID-19 experience are used to craft a more equitable, accessible, and efficient clinical research system that protects patient safety, ensures scientific integrity, and maintains data quality. The specific goals are: (1) ensure that clinical research is accessible, affordable, and equitable; (2) design more pragmatic and efficient clinical trials; (3) minimize administrative and regulatory burdens on research sites; (4) recruit, retain, and support a well-trained clinical research workforce; and (5) promote appropriate oversight and review of clinical trial conduct and results. Similarly, ASCO also organized its recommendations regarding cancer care delivery around five goals: (1) promote and protect equitable access to high-quality cancer care; (2) support safe delivery of high-quality cancer care; (3) advance policies to ensure oncology providers have sufficient resources to provide high-quality patient care; (4) recognize and address threats to clinician, provider, and patient well-being; and (5) improve patient access to high-quality cancer care via telemedicine. ASCO will work at all levels to advance the recommendations made in this report.